Industry · Pharmaceutical
Virtual CFOs for pharma — multi-entity, regulator-ready, margin-aware.
Compliance reporting, multi-entity consolidation, and margin diagnostics for pharma companies that have outgrown their in-house finance team.
Where it hurts
The pharmaceutical pains we step into.
Fuel and logistics cost shocks
Cold-chain logistics doesn't reprice on a 30-day notice. We model the shock against your gross margin so the price-list conversation has data behind it.
Compliance reporting (SAHPRA / FDA / EMA)
Regulator reporting has its own calendar, its own definitions, and almost no overlap with your management pack. We separate them cleanly so audit-time isn't crisis-time.
Multi-entity consolidation
ZA + offshore subsidiary + a captive distributor + a holdings company is normal in pharma. A clean consolidation pack is not. We build one.
Pricing under medical aid / insurance pressure
Net-net price after rebates is the only price that matters. We track it per SKU and surface where you're funding someone else's margin.
What "fixed" looks like
Outcomes we work toward, 90 days in.
Pattern-based engagements drawn from a CIMA-CGMA finance career. Not client-specific case studies — the first published case studies launch with our pilot customers in 2026.
Pattern 1 of 3
Two outputs, one ledger
The situation: Audit week feels like a rebuild week. The regulator pack and the management pack don't share a number anywhere.
What we do
- Restructure the chart of accounts so regulator + management views derive from the same ledger.
- Keep audit-evidence files current as a byproduct of the monthly close, not a sprint in March.
- Map SAHPRA / FDA / EMA reporting deadlines onto a 12-month calendar with owners.
Outcome shape
Audit week becomes review week, not rebuild week. Close-cycle compresses by 3–5 working days in the patterns we've worked.
Pattern 2 of 3
The multi-entity consolidation pack
The situation: A ZA holdco, an offshore sub, and a captive distributor — three trial balances and no single source of truth.
What we do
- Eliminations, FX revaluation, and intercompany reconciliation matched monthly.
- IFRS-compliant group pack ready when the parent or auditor asks.
- One-pager that shows the group through the auditor's eyes and the operator's eyes side-by-side.
Outcome shape
Group consolidation moves from quarterly fire-drill to a monthly byproduct. Auditor sign-off conversations get materially shorter.
Pattern 3 of 3
The net-net margin map
The situation: List-price margin looks fine on paper. Net-net margin after rebates, listing fees, and medical-aid pricing tells a different story.
What we do
- Per-SKU, per-channel margin built after all rebates and listing fees.
- 5-scenario fuel + logistics sensitivity layered over each SKU.
- Kill-list ranked by contribution leakage — taken into the next price-list conversation.
Outcome shape
The kill list usually surprises the founder. Pricing decisions stop being made on list-price gut and start being made on net-net data.
Outcome shapes are directional and drawn from JD's prior engagements. Your situation will differ — the free 30-minute diagnostic is where we calibrate.
Most-relevant seats
The right people for pharmaceutical.
Frequently asked
The questions you'd ask if we were across the table.
Regulator-ready and margin-aware — one finance brain, one ledger.
Walk into the boardroom. Pick the Advisory Specialist or the Virtual CFO. The first 30-minute consultation is on us.